A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Principal Investigator
David MaberleyOverview
Body Locations and Systems
Macular DegenerationClinicalTrials.gov#
NCT02307682Status
Closed for RecruitmentStudy Start/End
Jul 21, 2015 to Dec 29, 2017Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Theresa Wiens, Research Manager Phone
604-875-4111 ext.62544Email Address
twiens@eyecarecentre.orgPurpose of Study
The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.